Avid Bioservices Inc (CDMO)

[Couch]

You can't have it both ways. And by wanting to retain 100% of the IP, they sent a clear message that dilution will continue until bavituximab is on the market

This seems to be speaking to a different possibility.
Steve King: Just to expand on that a little bit, our stated goal has been ex-U.S. partnering, to primarily keep as much of the U.S. rights as we can, and that remains intact.